HighLife has secured FDA Breakthrough Device designation for its trans-septal mitral valve replacement system, marking another important step forward in the structural heart space.
The designation is designed to support devices that may offer a meaningful improvement over existing treatment options for serious conditions with unmet clinical needs. For HighLife, this is a strong validation of its TMVR approach, which is being developed for patients with moderate to severe mitral regurgitation.
What makes the technology particularly interesting is its minimally invasive, beating heart approach. The system uses a valve-in-ring concept, with both components implanted percutaneously, offering a potential alternative for patients who may not be suitable for surgery or other transcatheter options.
With CE Mark approval now enabling use in Europe and FDA Breakthrough Device designation supporting the US pathway, HighLife is clearly gaining momentum on both sides of the Atlantic.
For the wider market, this is another strong signal of where structural heart innovation is heading: less invasive procedures, broader treatment options, and faster routes to patient access.